Quality-by-design-steered development of luliconazole-loaded ultra-deformable ethosomes for topical delivery: improved dermatokinetics and antifungal activity

This work reports the first systematic formulation strategy guided by Quality-by-Design (QbD) principles to create an ultra-deformable ethosomes (UDEs) based nanocarrier for luliconazole (LCZ). The approach addresses the long-standing barriers of poor solubility, limited skin penetration, and rapid drug clearance in dermatophytosis therapy. A Box-Behnken design identified the optimal composition, including phospholipid (PL 90G), Span® 20, and ethanol: propylene glycol, yielding highly elastic nanosized vesicles (particle size 196.97 ± 1.57 nm; polydispersity index 0.158 ± 0.03) with exceptional percent drug entrapment (91.0%) and sustained release (62% over 12 h). Incorporation into a Carbopol 980 gel conferred favourable shear-thinning behaviour, enhanced spreadability, and superior texture as compared to a marketed 1% LCZ cream (MKT-LF). Ex vivo permeation across rat skin demonstrated a 2.4-fold higher flux and 11.3-fold greater cutaneous deposition than MKT-LF, attributed to synergistic vesicle deformability and ethanol-induced fluidization of stratum corneum. LCZ-UDEs demonstrated deep epidermal penetration of intact fluorescently labelled vesicles. Dermatokinetic profiling revealed a 3.4-fold increase in epidermal AUC<sub>0-12</sub>, prolonged half-life, and delayed T<sub>max</sub>, indicating enhanced skin retention. Antifungal assays demonstrated a two-fold reduction in MIC, and rapid fungicidal kinetics against Trichophyton rubrum compared with LCZ solution and MKT-LF. Biocompatibility studies validated >90% HaCaT cell viability, no haemolysis, and absence of dermal irritation. Sustained intradermal LCZ levels minimized sub-therapeutic exposure that drives fungal resistance. By uniting nanoscale vesicle engineering, ethanol-enhanced skin permeation, and QbD-optimized composition, this study delivers a stable, safe, and efficacious topical nanoplatform with potential to transform dermatophytosis management and mitigate antifungal resistance.

Institutions

Publication Details

Journal
International Journal of Pharmaceutics
Published
2025-12-18
DOI
https://doi.org/10.1016/j.ijpharm.2025.126514
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Quality-by-design-steered development of luliconazole-loaded ultra-deformable ethosomes for topical delivery: improved dermatokinetics and antifungal activity

International Journal of Pharmaceutics
Advancements in Transdermal Drug Delivery
article

Quality-by-design-steered development of luliconazole-loaded ultra-deformable ethosomes for topical delivery: improved dermatokinetics and antifungal activity

article en

Abstract

This work reports the first systematic formulation strategy guided by Quality-by-Design (QbD) principles to create an ultra-deformable ethosomes (UDEs) based nanocarrier for luliconazole (LCZ). The approach addresses the long-standing barriers of poor solubility, limited skin penetration, and rapid drug clearance in dermatophytosis therapy. A Box-Behnken design identified the optimal composition, including phospholipid (PL 90G), Span® 20, and ethanol: propylene glycol, yielding highly elastic nanosized vesicles (particle size 196.97 ± 1.57 nm; polydispersity index 0.158 ± 0.03) with exceptional percent drug entrapment (91.0%) and sustained release (62% over 12 h). Incorporation into a Carbopol 980 gel conferred favourable shear-thinning behaviour, enhanced spreadability, and superior texture as compared to a marketed 1% LCZ cream (MKT-LF). Ex vivo permeation across rat skin demonstrated a 2.4-fold higher flux and 11.3-fold greater cutaneous deposition than MKT-LF, attributed to synergistic vesicle deformability and ethanol-induced fluidization of stratum corneum. LCZ-UDEs demonstrated deep epidermal penetration of intact fluorescently labelled vesicles. Dermatokinetic profiling revealed a 3.4-fold increase in epidermal AUC<sub>0-12</sub>, prolonged half-life, and delayed T<sub>max</sub>, indicating enhanced skin retention. Antifungal assays demonstrated a two-fold reduction in MIC, and rapid fungicidal kinetics against Trichophyton rubrum compared with LCZ solution and MKT-LF. Biocompatibility studies validated >90% HaCaT cell viability, no haemolysis, and absence of dermal irritation. Sustained intradermal LCZ levels minimized sub-therapeutic exposure that drives fungal resistance. By uniting nanoscale vesicle engineering, ethanol-enhanced skin permeation, and QbD-optimized composition, this study delivers a stable, safe, and efficacious topical nanoplatform with potential to transform dermatophytosis management and mitigate antifungal resistance.

International Journal of PharmaceuticsVol. 690
University of Lancashire (GB), Panjab University (IN)
Openalex Percentile: Top 66%
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Quality-by-design-steered development of luliconazole-loaded ultra-deformable ethosomes for topical delivery: improved dermatokinetics and antifungal activity · International Journal of Pharmaceutics (2025) | TGRS Research Map | TGRS